Xeris Biopharma Holdings, Inc. SEC filings XERS
Xeris Biopharma Holdings, Inc. has 345 filings in SEC EDGAR's recent list, going back to Jul 2, 2021. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 21, 2026 | Apr 20, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 2, 2026 | Mar 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 27, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 1, 2025 | Dec 1, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 3, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 28, 2025 | Mar 28, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Results of operations
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2024 | Nov 8, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 2, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Jul 8, 2024 | Jul 7, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 5, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Other events
|
Mar 6, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 4, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2023 | Oct 16, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 29, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 27, 2023 | Sep 26, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 28, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 29, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Auditor change
|
Mar 17, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Material agreement
|
Jan 20, 2023 | Jan 19, 2023 |
| 8-K |
Current report
Results of operations
|
Jan 5, 2023 | Jan 5, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 20, 2022 | Oct 20, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 3, 2022 | Sep 29, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Other events
|
Mar 10, 2022 | Mar 8, 2022 |
| 8-K |
Current report
Other events
|
Jan 28, 2022 | Jan 28, 2022 |
| 8-K |
Current report
Results of operations
|
Jan 18, 2022 | Jan 18, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jan 3, 2022 | Jan 2, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Other events
|
Oct 8, 2021 | Oct 5, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 5, 2021 | Oct 5, 2021 |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XERS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1867096
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.